Microparticles containing erlotinib-loaded solid lipid nanoparticles for treatment of non-small cell lung cancer

Area of Science:

• Pharmaceutical Sciences
• Nanotechnology
• Oncology

Background:

• Non-small cell lung cancer (NSCLC) with EGFR mutations often requires targeted therapy.
• Erlotinib (ETB), an EGFR tyrosine kinase inhibitor (TKI), is a common treatment, but local delivery could improve efficacy.
• Current oral delivery of ETB may have limitations for localized lung cancer treatment.

Purpose of the Study:

• To develop and characterize an erlotinib-loaded solid lipid nanoparticle dry powder inhaler (ETB-SLN DPI) for enhanced NSCLC treatment.
• To evaluate the cytotoxicity and in vitro inhalation properties of the ETB-SLN DPI formulation.

Main Methods:

• Formulation of ETB-loaded solid lipid nanoparticles (SLNs) using compritol/poloxamer 407.
• Characterization of SLNs for size, shape, and encapsulation efficiency.
• Evaluation of cytotoxicity using MTT assay and DAPI staining in A549 NSCLC cells.
• Development of ETB-SLN DPI via spray drying with mannitol and assessment of powder properties and aerodynamic performance using NGI.

Main Results:

• ETB-SLNs exhibited a sub-100 nm spherical shape with 78.21% encapsulation efficiency.
• ETB-SLNs demonstrated enhanced cytotoxicity in A549 cells compared to free erlotinib.
• The ETB-SLN DPI formulation showed suitable flowability, aerodynamic characteristics, and deep lung deposition potential.

Conclusions:

• The developed ETB-SLN DPI is a promising formulation for localized delivery of erlotinib in NSCLC treatment.
• This novel nanocarrier-based dry powder inhaler offers potential for improved therapeutic outcomes in NSCLC patients.
• The study highlights the potential of solid lipid nanoparticles and dry powder inhalation for targeted cancer therapy.